Open Access<p>Prescription Status and Clinical Outcomes of Methylxanthines and Leukotriene Receptor Antagonists in Mild-to-Moderate Chronic Obstructive Pulmonary Disease</p>
Author(s) -
Jung Kyu Lee,
Chin Kook Rhee,
Kyungjoo Kim,
Seung Won,
Jaeha Lee,
Ji Ye Jung,
Kwang-Ha Yoo,
Yoo Il Kim,
Deog Kyeom Kim
Publication year - 2019
Publication title -
international journal of chronic obstructive pulmonary disease/international journal of copd
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 67
eISSN - 1178-2005
pISSN - 1176-9106
DOI - 10.2147/copd.s216326
Subject(s) - medicine , copd , asthma , medical prescription , exacerbation , comorbidity , bronchodilator , physical therapy , pharmacology
Methylxanthines and leukotriene receptor antagonists (LTRA) are not a first-line medical treatment for chronic obstructive pulmonary disease (COPD) but are frequently prescribed despite limited evidence. We aimed to elucidate the real prescribing status and clinical impacts of these agents in early COPD patients.